ARASTEP trial evaluates darolutamide plus ADT for high-risk biochemical recurrence of prostate cancer, focusing on radiologic progression-free survival (rPFS) by PSMA PET-CT. The study involves 970 ...

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

Results of subgroup analyses of the phase 3 CREST trial (NCT04165317) evaluating sasanlimab plus BCG compared with BCG alone ...

UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...

Paul E. Dato, MD, discusses how a 69-year-old Black man presented with metastatic hormone-sensitive prostate cancer, showing symptoms of fatigue, nocturia, back pain, and weight loss, with initial ...

Investigators found that benefits of treatments that are observed in trials also appear in the real world. A recent study examined the relationship between randomized controlled trials and real-world ...

Merrill discusses the evolving non–muscle invasive bladder cancer treatment space. Expanded access programs (EAPs), such as a recently FDA-authorized EAP in which ImmunityBio is partnering with the ...

Please share your concluding thoughts about the recent progress and future outlook of NMIBC.

The TRAVERSE trial showed testosterone therapy's MACE risk is non-inferior to placebo, reassuring prescribers and patients. Despite the updated labeling, caution is advised due to potential venous ...

Nadofaragene firadenovec achieved a 79% complete response rate in CIS patients at three months, with durable responses at six and nine months. Real-world safety data showed mostly low-grade, transient ...